Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -109.89M | -29.02M | -38.55M | -19.12M | 64.50M |
| Total Depreciation and Amortization | 101.70M | 97.31M | 91.56M | 85.39M | 80.69M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 109.69M | 82.27M | 69.48M | 34.53M | 29.49M |
| Change in Net Operating Assets | -81.59M | -67.31M | -75.16M | -28.93M | 12.38M |
| Cash from Operations | 19.91M | 83.26M | 47.33M | 71.88M | 187.06M |
| Capital Expenditure | -1.12M | -1.01M | -1.34M | -1.12M | -1.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -293.09M | -293.09M | -293.09M | -293.09M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 279.49M | 241.68M | 298.54M | 337.00M | -81.74M |
| Cash from Investing | -14.73M | -52.43M | 4.11M | 42.78M | -82.94M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.09M | 49.24M | 37.62M | 35.94M | 15.66M |
| Repurchase of Common Stock | -5.49M | -5.44M | -4.23M | -5.19M | -4.76M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13.10M | -4.16M | -24.26M | -24.26M | -22.40M |
| Cash from Financing | 31.51M | 39.64M | 9.13M | 6.49M | -11.50M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.69M | 70.47M | 60.57M | 121.15M | 92.62M |